Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations

"Objective: The latest nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) is indicated for human immunodeficiency virus type-1 (HIV-1) patients initiating antiretroviral treatment, but the extent of genotypic RPV resistance in treatment-naive patients outside clinical trial...

Descripción completa

Detalles Bibliográficos
Autores Principales: "Theys, Kristof, Van Laethem, Kristel, Gomes, Perpetua, Baele, Guy, Pineda-Peña, Andrea-Clemencia, Vandamme, Anne-Mieke, Camacho, Ricardo J., Abecasis, Ana B."
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: Mary Ann Liebert Inc. 2016
Materias:
Acceso en línea:https://repository.urosario.edu.co/handle/10336/23941
https://doi.org/10.1089/aid.2015.0095